Vaccine maker shaping global immunization
The Oxford/Bundibugyo Ebola vaccine candidate is entering Phase I trials in the UK, with 50 healthy adults aged 18-55 tested for safety and immune response. 620,000 doses are stockpiled and 4,000 doses are being used for the study, as researchers push rapid development in response to the Bundibugyo outbreak in the Congo.